Management of Severe Symptomatic Bradycardia

Initial Assessment and Stabilization

• Identify symptomatic bradycardia by altered mental status, ischemic chest discomfort, acute heart failure, systolic blood pressure < 90 mm Hg, or other shock signs that persist despite a secured airway and adequate breathing. (ACC, Class IIa, Level B) 1
• Provide supplemental oxygen promptly when hypoxemia or increased work of breathing is present, as hypoxemia is a common reversible cause of bradycardia. (ACC, Class I) 2
• Obtain large‑bore IV access, attach continuous cardiac monitoring, and acquire a 12‑lead ECG to define the rhythm and locate any conduction block; do not delay therapy while performing these steps. (ACC, Class I) 2
• Determine the anatomic level of atrioventricular (AV) block: AV‑nodal blocks (second‑degree type I or third‑degree with narrow‑complex escape) may respond to atropine, whereas infranodal blocks (wide‑complex escape, typically with anterior MI) do not and atropine is contraindicated. (ACC, Class III) 3

First‑Line Pharmacologic Therapy – Atropine

• Atropine is the recommended initial drug for acute symptomatic bradycardia. (ACC, Class IIa, Level B) 1
• Dosing: 0.5 mg IV bolus every 3–5 minutes until symptoms resolve or heart rate reaches ≈ 60 bpm; titrate up to a cumulative maximum of 2.0 mg, which produces complete vagal blockade. (ACC, Class IIa, Level B) 3
• Pitfall: Doses < 0.5 mg are sub‑therapeutic and can paradoxically worsen bradycardia via a parasympathomimetic response; therefore, never administer less than 0.5 mg. (ACC, Class III) 3
• Effective indications:
  
  • Symptomatic sinus bradycardia (heart rate < 50 bpm with hypotension, ischemia, or escape ventricular arrhythmia). (ACC, Class IIa, Level B) 3
  • Symptomatic AV block at the AV‑nodal level (second‑degree type I or third‑degree with narrow‑complex escape). (ACC, Class IIa, Level B) 3
  • Sinus bradycardia occurring within 6 hours of acute myocardial infarction (especially right‑coronary‑artery involvement or after thrombolysis). (ACC, Class IIa, Level B) 3
• Contraindications: Infranodal AV block (wide‑complex escape rhythm, usually with anterior MI) – atropine provides no benefit and may worsen outcomes. (ACC, Class III) 3
• Use atropine with caution in acute MI because parasympathetic tone can protect against ventricular fibrillation and infarct extension. (ACC, Class IIb, Level B) 3

Second‑Line Interventions When Atropine Fails

Transcutaneous Pacing (TCP)

• Initiate TCP immediately if bradycardia with hypotension persists after a total of 2.0 mg atropine. (AHA, Class IIa, Level B) 1
• Indications for TCP:
  
  • Sinus bradycardia < 50 bpm with systolic blood pressure < 80 mm Hg unresponsive to drug therapy. (ACC, Class IIa) 4
  • Symptomatic bradycardia with hypotension that does not improve after atropine. (ACC, Class IIa) 4
  • Mobitz type II second‑degree AV block. (ACC, Class IIa) 4
• Apply transcutaneous pacing pads early—ideally while administering atropine—to enable rapid activation if needed. (ACC, Class I) 3
• Verify both electrical and mechanical capture during pacing by checking pulse, arterial waveform, pulse‑oximetry, or continuous end‑tidal CO₂; electrical artifact alone can be misleading. (AHA, Class I) 1
• TCP is painful in conscious patients; administer analgesics or anxiolytics to ensure tolerance. (AHA, Class I) 1
• Use TCP as a bridge to definitive therapy (transvenous pacing or permanent pacemaker). (ACC, Class IIa) 3
• Evidence: A 2006 systematic review found no overall survival benefit of pre‑hospital TCP versus standard advanced life support, although a subgroup analysis suggested possible benefit in symptomatic bradycardia. (AHA, Level B) 1
• Recent studies highlight persistent challenges in achieving true capture, emphasizing the need for reliable confirmation methods. (AHA, Level B) 1

Vasopressor Infusion

• When atropine fails and TCP is unavailable or ineffective, start an IV infusion of epinephrine or dopamine. (AHA, Class IIb, Level B) 1
• Dopamine is an acceptable alternative to raise heart rate and blood pressure. (AHA, Class IIb, Level B) 1
• A randomized feasibility trial comparing dopamine to TCP after atropine failure showed no difference in survival to discharge. (AHA, Level B) 1
• Push‑dose epinephrine is increasingly used for acute bradycardia with hypotension, but specific evidence for bradycardia is limited; careful dosing is essential to avoid medication errors and adverse hemodynamic effects. (AHA, Class IIb, Level B) 1
• Selection between TCP and vasopressor therapy should consider clinician experience, resource availability, and the speed of hemodynamic response required. (AHA, Class IIb, Level B) 1

Advanced Pacing – Temporary Transvenous Pacing

• Indicated for patients refractory to both pharmacologic therapy and TCP. (AHA, Class IIa, Level C) – citation not required for this statement (no specific reference).
• Complication rates for temporary transvenous pacing range from 14 % to 40 % (including bloodstream infection, pneumothorax, vascular injury). (AHA, Level B) 1
• Transfer patients to a facility with expertise in transvenous pacing when this modality is needed. (ACC, Class IIa, Level B) 4

Special Clinical Scenarios

Acute Myocardial Infarction

• For new or indeterminate bifascicular block (RBBB + LAFB/LPFB or LBBB) with first‑degree AV block, consider prophylactic TCP. (ACC, Class II) 4
• For Mobitz type II AV block or bilateral bundle‑branch block, prepare for transvenous pacing. (ACC, Class II) 4
• Persistent second‑degree AV block in the His‑Purkinje system with bilateral BBB or complete heart block after acute MI warrants permanent pacing. (ACC, Class I) 4

Reversible Causes

• Identify and treat reversible etiologies (beta‑blocker, calcium‑channel‑blocker, digoxin toxicity; hyper‑kalemia; hypothyroidism; hypothermia; acute ischemia). (AHA, Class I) 1

Asymptomatic or Minimally Symptomatic Bradycardia

• Do not treat asymptomatic sinus bradycardia. (ACC, Class III) 3

Definitive Management

• Permanent pacemaker implantation is the only definitive therapy for persistent symptomatic bradycardia due to sinus‑node dysfunction or high‑grade AV block. (ACC, Class I, Level A) 5

Management of Acute Hypotension with Bradycardia

Initial Assessment

• Hemodynamic instability is defined by any of the following persisting despite adequate airway and breathing: altered mental status, ischemic chest discomfort, acute heart failure, systolic blood pressure < 90 mm Hg, or other signs of shock.  6

First‑Line Pharmacologic Therapy (Atropine)

• Atropine 0.5 mg IV is the recommended initial drug for symptomatic bradycardia with hypotension; it should be titrated in 0.5‑mg increments to achieve a heart rate of ≈ 60 bpm, with a maximum cumulative dose of 2.0 mg.  Class IIa, Level B (American Heart Association). 6
• Doses < 0.5 mg may paradoxically worsen bradycardia by eliciting a parasympathomimetic response. 7
• The drug is especially effective for sinus bradycardia associated with hypotension when it occurs within 6 hours of an acute myocardial infarction or after thrombolytic therapy involving the right coronary artery. 7
• Contraindication (Class III, Harm): Atropine should not be used for infranodal AV block (e.g., anterior MI with wide‑complex escape rhythm). 7
• Caution: In the setting of acute MI, atropine may diminish the protective parasympathetic tone that limits ventricular fibrillation and infarct extension. 7

Second‑Line Interventions When Atropine Fails

Transcutaneous Pacing (TCP)

• If bradycardia with hypotension remains unresponsive after adequate atropine, initiate TCP immediately. Class IIa, Level B (American Heart Association). 6
• Indications for TCP include:
  
  • Sinus bradycardia < 50 bpm with systolic BP < 80 mm Hg unresponsive to drug therapy. 7
  • Symptomatic bradycardia with hypotension that does not improve after atropine. 7
  • High‑degree AV block when IV access is unavailable (Class IIb). 6
• Practical points: apply transcutaneous patches and prepare the device for rapid activation; verify capture by checking a pulse or arterial waveform. 8
• TCP is painful; analgesic or anxiolytic medication should be administered to conscious patients. 8
• Patients likely to require prolonged pacing should be transitioned to a temporary transvenous pacemaker because of TCP‑related discomfort. 8

Vasopressor Infusion

• When atropine fails and TCP is not immediately feasible or effective, start an IV infusion of a β‑adrenergic agonist (e.g., dopamine or epinephrine) to increase heart rate and blood pressure. Class IIb, Level B (American Heart Association). 6

Advanced Interventions

Temporary Transvenous Pacing

• Indicated for patients refractory to pharmacologic therapy and TCP. Class IIa, Level C (American Heart Association). 6
• Complication rates for temporary transvenous pacing range from 14 % to 40 %, with infection risk heightened when a temporary wire precedes a permanent implant. 8
• In mildly to moderately symptomatic patients with intermittent bradycardia without hemodynamic compromise, the risks of transvenous pacing outweigh the benefits. 8
• Transfer the patient to a facility equipped and experienced in placing transvenous systems. 7

Etiology‑Guided Management

• Sinus node dysfunction is most often age‑related fibrosis; establishing a temporal link between symptoms and bradycardia is essential before considering permanent pacing. 9
• AV block location:
  
  • AV‑nodal block (second‑degree type I or third‑degree with narrow‑complex escape) may respond to atropine. 7
  • Infranodal block (e.g., anterior MI with wide‑complex escape) is a contraindication for atropine (Class III). 7

Common Pitfalls (Evidence‑Based)

• Underdosing atropine (< 0.5 mg) can aggravate bradycardia. 7
• Using atropine in infranodal block is contraindicated and may worsen outcomes. 7
• Delaying TCP preparation in unstable patients increases the risk of prolonged hypotension; patches should be placed early even while atropine is being administered. 8
• Premature transition to transvenous pacing should be avoided given the high complication profile (14‑40 %). 8

Evidence‑Based Management of Hemodynamically Unstable Metoprolol Overdose

Initial Pharmacologic Management

• Administer atropine 0.5 mg IV as the first‑line drug for symptomatic bradycardia with hypotension; this is a Class IIa recommendation from the American Heart Association (AHA). 10

Atropine Dosing Protocol and Pitfalls

• Give 0.5 mg IV boluses of atropine every 3–5 minutes until the desired effect is reached. 11
• Target a heart rate of approximately 60 beats/min when titrating atropine. 10
• Do not exceed a cumulative dose of 2.0 mg, which achieves complete vagal blockade. 11
• Peak hemodynamic effect of each atropine dose occurs within 3 minutes of administration. 12
• Avoid doses < 0.5 mg, as sub‑therapeutic amounts can paradoxically worsen bradycardia via central vagal stimulation. 11

Second‑Line Mechanical Intervention: Transcutaneous Pacing (TCP)

• If bradycardia and hypotension persist after a total of 2.0 mg atropine, initiate transcutaneous pacing immediately; this is a Class IIa recommendation for symptomatic bradycardia with systolic BP < 80 mmHg unresponsive to drug therapy (AHA). 13
• Confirm both electrical capture and mechanical capture (pulse or arterial waveform) before relying on pacing. 13
• Provide analgesia or anxiolytics because TCP is painful in conscious patients. 14
• Use TCP as a bridge to definitive therapy (e.g., high‑dose insulin). 10

Adjunctive Vasopressor Support

• Start an epinephrine infusion at 0.05–0.5 µg/kg/min when hypotension remains despite atropine and/or pacing. 13
• Dopamine infusion is an acceptable alternative for refractory hypotension. 13
• 2025 AHA guidelines endorse epinephrine or dopamine as reasonable alternatives when atropine alone is insufficient. (Class IIb) 13

Interventions That Should Not Be Used

• Cardioversion is contraindicated because the clinical picture involves bradycardia, not a tachyarrhythmia such as ventricular tachycardia or atrial fibrillation. 11

Summary of Evidence Hierarchy

• The recommendations above are derived from AHA guideline statements (Class IIa or IIb) and peer‑reviewed cardiology literature spanning 1990–2025, providing moderate to strong evidence for the outlined management steps.

Transvenous Pacing in Beta‑Blocker Toxicity

Initial Pharmacologic Management

• Atropine 0.5 mg IV bolus every 3–5 minutes (up to a cumulative 2 mg) is recommended until heart rate reaches ~60 bpm or symptoms resolve – the maximal dose is based on the Circulation guideline. 15
• Atropine doses <0.5 mg should be avoided because they may paradoxically worsen bradycardia via parasympathomimetic effects – recommendation from the American College of Cardiology. 16
• Atropine is contraindicated in infranodal (wide‑complex escape) AV block, which can occur with beta‑blocker toxicity affecting His‑Purkinje conduction – American College of Cardiology guidance. 16

Mechanical Pacing Strategies

• If systolic blood pressure remains <80 mm Hg after 2 mg atropine, transcutaneous pacing should be initiated immediately – Circulation and American College of Cardiology protocols. 15, 17
• Transcutaneous patches should be applied early, ideally while atropine is being administered, to allow rapid activation – American College of Cardiology recommendations. 16, 17
• Both electrical and mechanical capture must be confirmed (pulse, arterial waveform, or pulse oximetry) because electrical artifact alone is misleading – Circulation guideline. 15
• Analgesics or anxiolytics are required for conscious patients because transcutaneous pacing is painful – American College of Cardiology and Circulation statements. 16, 15
• When atropine fails and transcutaneous pacing is unavailable or ineffective, start IV epinephrine (0.05–0.5 µg·kg⁻¹·min⁻¹) or dopamine infusion to accelerate heart rate while preparing for definitive pacing – Circulation recommendation. 15

Indications for Transvenous Pacing

• Transvenous pacing is reasonable for persistent hemodynamically unstable bradycardia that is refractory to maximal atropine (2 mg) and transcutaneous pacing – American College of Cardiology guideline. 18
• Intolerable pain despite adequate analgesia during transcutaneous pacing warrants conversion to transvenous pacing – American College of Cardiology evidence. 16, 17
• Patients expected to require prolonged pacing (high‑risk cases) should receive transvenous pacing because transcutaneous pacing is unsuitable for extended use due to discomfort – American College of Cardiology data. 16, 17
• Recurrent sinus pauses >3 seconds that do not respond to atropine are an indication for transvenous pacing – American College of Cardiology observations. 16, 17

Complications and Risks

• Temporary transvenous pacing carries a complication rate of 14 %–40 %, including bloodstream infection, pneumothorax, vascular injury, electrode displacement, and cardiac tamponade – data from the Journal of the American College of Cardiology. 18

Guideline Recommendations

• The 2019 ACC/AHA/HRS bradycardia guidelines assign transvenous pacing a Class IIa (reasonable) recommendation with Level C evidence for persistent hemodynamically unstable sinus node dysfunction refractory to medical therapy – ACC/AHA/HRS guideline. 18
• The Class IIa/Level C rating reflects the absence of randomized trials comparing pacing strategies and reliance on observational studies – supporting evidence from the Journal of the American College of Cardiology. 19

Special Considerations in Beta‑Blocker Toxicity

• Beta‑blocker toxicity can produce both sinus bradycardia and high‑degree AV block, depending on the specific agent and dose – Critical Care review. 20
• In severe beta‑blocker poisoning, pacemaker placement was required in 50 %–100 % of cases, with bradycardia/hypotension lasting a median of 25–120 hours – EXTRIP systematic review. 20
• Transvenous pacing serves as a bridge to definitive therapies (e.g., high‑dose insulin euglycemic therapy, lipid emulsion, extracorporeal support) rather than a definitive treatment – Critical Care guidance. 20

Contraindications (Class III: Harm)

• Transvenous pacing should not be performed in patients with minimal or infrequent symptoms without hemodynamic compromise – American College of Cardiology recommendation. 18
• First‑degree AV block alone is a contraindication – American College of Cardiology statements. 16, 17
• Type I second‑degree AV block with normal hemodynamics is a contraindication – American College of Cardiology guidance. 16, 17
• Asymptomatic bradycardia is a contraindication – American College of Cardiology evidence. 16, 17

Practical Implementation

• Patients requiring transvenous pacing should be transferred to a facility equipped and experienced in placing transvenous systems – American College of Cardiology recommendation. 16, 17
• Preferred venous access is the internal jugular vein; alternative routes include subclavian or femoral veins – American College of Cardiology guidance. 16, 17
• The risk of infection increases when temporary pacing precedes permanent pacemaker implantation; therefore, the duration of temporary pacing should be minimized – American College of Cardiology guideline. 18